2-t-Butoxycarbonyl-1-carboxyperhydroisoindole | 118125-08-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-t-Butoxycarbonyl-1-carboxyperhydroisoindole
• 英文别名: octahydro-isoindole-1,2-dicarboxylic acid 2-tert-butyl ester；N-BOC-octahydroisoindole-1-carboxylic acid；2-[(2-methylpropan-2-yl)oxycarbonyl]-1,3,3a,4,5,6,7,7a-octahydroisoindole-1-carboxylic acid
• CAS: 118125-08-9
• 化学式: C₁₄H₂₃NO₄
• 分子量: 269.341
• InChiKey: AIBSQHAPZPSICF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-t-Butoxycarbonyl-1-carboxyperhydroisoindole 在 乙醚 作用下， 以 盐酸 、 1,4-二氧六环 为溶剂， 反应 1.0h， 以to afford octahydroisoindole-1-carboxylic acid (4.13 g) as a white solid的产率得到八氢-1H-异吲哚-1-羧酸
  参考文献：
  名称：

  N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors

  摘要：

  公式I的化合物是VLA-4和/或alpha4/beta7的拮抗剂，因此在细胞黏附和细胞黏附介导的病理过程的抑制或预防方面是有用的。这些化合物可以制成药物组合物，适用于治疗艾滋病相关痴呆症、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病，包括溃疡性结肠炎和克罗恩病、炎症性肺部疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、视网膜炎、类风湿性关节炎、败血性关节炎、中风、肿瘤转移、葡萄膜炎和I型糖尿病的治疗。

  公开号：

  US06855708B2
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 八氢-1H-异吲哚-1-羧酸 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.5h， 以72%的产率得到2-t-Butoxycarbonyl-1-carboxyperhydroisoindole
  参考文献：
  名称：

  [EN] [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS
  [FR] DERIVES DE PROLINE BICYCLIQUES 20041028US2003008861A1LIN LINUS S [US], et al20030109example 10, step C example 11, step A example 29, step c (starting material)X2,8XBERGMEIER S C ET AL: "Synthesis of Bicyclic Proline Analogs Using a Formal [3 + 2] Intramolecular Aziridine-Allylsilane Cycloaddition Reaction", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 55, no. 26, 25 June 1999 (1999-06-25), pages 8025 - 8038, XP004168571, ISSN: 0040-4020BERGMEIER S C ET ALSynthesis of Bicyclic Proline Analogs Using a Formal [3 + 2] Intramolecular Aziridine-Allylsilane Cycloaddition ReactionTETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL1999062555260040-40208025803845Scheme 7X2XDATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002288925, Database accession no. BRN:388906BEILSTEINBEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DEBRN:388906AX4XMURAYAMA ET AL, YAKUGAKU ZASSHI, vol. 85, 1965, pages 765 - 769MURAYAMA ET ALYAKUGAKU ZASSHI196585765769WO0027808A1AVENTIS PHARMA GMBH [DE]20000518214814211517A1-9AWO03074048A1WARNER LAMBERT CO [US], et al2003091235253626PX1-9PXOTHMAN M ET AL: "New Fused Lactones from Indolizinediones via N-Acyliminium Ions", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 54, no. 30, 23 July 1998 (1998-07-23), pages 8737 - 8744, XP004124041, ISSN: 0040-4020OTHMAN M ET ALNew Fused Lactones from Indolizinediones via N-Acyliminium IonsTETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL1998072354300040-4020873787443A-EScheme 1X1XGUILLERM G ET AL: "Synthesis of Hydroxylated Pyrrolidines Derivatives as Potential Inhibitors of SAH/MTA Nucleosidase", TETRAHEDRON LETTERS, vol. 28, no. 5, 1987, pages 535 - 538, XP002288924GUILLERM G ET ALSynthesis of Hydroxylated Pyrrolidines Derivatives as Potential Inhibitors of SAH/MTA NucleosidaseTETRAHEDRON LETTERS19872855355384AScheme 2X1X

  摘要：

  本发明涉及一种[c]-融合的双环脯氨酸衍生物，或其药用可接受的盐；包括该化合物或其盐的药物组合物；以及治疗疾病的方法，包括但不限于预防或抑制关节软骨损伤，以及预防或治疗以关节软骨损伤、关节炎或关节疼痛为特征的疾病的方法。[c]-融合的双环脯氨酸衍生物是如上所述的I式化合物。以关节软骨损伤或关节疼痛为特征的疾病包括，例如，骨关节炎和类风湿性关节炎。类风湿性关节炎还以关节炎为特征。本发明还涉及合成和制备[c]-融合的双环脯氨酸衍生物或其药用可接受的盐的方法。

  公开号：

  WO2004092134A1

文献信息

• [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions
  申请人：Guzzo R. Peter

  公开号：US20050137215A1

  公开（公告）日：2005-06-23

  This invention relates to a compound which is [c]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [c]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [c]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种[c]-融合的双环脯氨酸衍生物化合物或其药学上可接受的盐；一种包括该化合物或其盐的制药组合物，以及治疗疾病的方法，包括但不限于预防或抑制关节软骨损伤和预防或治疗以关节软骨损伤、关节炎或关节疼痛为特征的疾病的方法。[c]-融合的双环脯氨酸衍生物是如上所述的化合物I。以关节软骨损伤或关节疼痛为特征的疾病包括骨关节炎和类风湿性关节炎等。类风湿性关节炎还表现为关节炎。本发明还涉及合成和制备[c]-融合的双环脯氨酸衍生物或其药学上可接受的盐的方法。
• Inhibitors of dipeptidyl peptidase iv
  申请人：Belyakov Sergei

  公开号：US20050070719A1

  公开（公告）日：2005-03-31

  Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, and of such other enumerated conditions as can be treated with inhibitors of DPP IV.

  本发明提供了二肽酶IV（DPP IV）的新型抑制剂，包括含有治疗有效量的DPP IV新型抑制剂的制药组合物，以及新型治疗医学状况的方法。本发明所描述的DPP IV新型抑制剂在治疗神经系统疾病、糖尿病、炎症性疾病如关节炎、肥胖症、骨质疏松症以及其他可用DPP IV抑制剂治疗的疾病方面非常有用。
• VLA-4 Antagonists
  申请人：Liu Ping

  公开号：US20090069376A1

  公开（公告）日：2009-03-12

  Substituted N—[N-(sulphonylphenyl)sulfonyl-prolyl]-phenylalanine derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells after oral administration and are suitable for once-, twice-, or thrice-a-day oral administration. This invention also relates to compositions containing such compounds and methods of treatment using such compounds.

  本发明的N-[N-(磺酰基苯基)磺酰基-脯氨酸]-苯丙氨酸衍生物是VLA-4整合素的拮抗剂，可用于治疗、预防和抑制通过VLA-4结合和细胞黏附和激活介导的疾病。此外，本发明的化合物在口服后表现出显著的VLA-4受体占有率，并适用于一天一次、两次或三次口服。本发明还涉及含有此类化合物的组合物和使用此类化合物的治疗方法。
• EP1615886A1
  申请人：——

  公开号：EP1615886A1

  公开（公告）日：2006-01-18
• VLA-4 ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1874299A2

  公开（公告）日：2008-01-09